The 10-second takeaway
For the quarter ended June 30 (Q2), Eli Lilly beat slightly on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue increased. Non-GAAP earnings per share increased significantly. GAAP earnings per share increased significantly.
Margins grew across the board.
Eli Lilly reported revenue of $5.93 billion. The 12 analysts polled by S&P Capital IQ predicted a top line of $5.84 billion on the same basis. GAAP reported sales were 5.9% higher than the prior-year quarter's $5.60 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $1.16. The 15 earnings estimates compiled by S&P Capital IQ predicted $1.01 per share. Non-GAAP EPS of $1.16 for Q2 were 40% higher than the prior-year quarter's $0.83 per share. GAAP EPS of $1.11 for Q2 were 34% higher than the prior-year quarter's $0.83 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 80.3%, 80 basis points better than the prior-year quarter. Operating margin was 26.4%, 490 basis points better than the prior-year quarter. Net margin was 20.3%, 380 basis points better than the prior-year quarter. (Margins calculated in GAAP terms.)
Next quarter's average estimate for revenue is $5.69 billion. On the bottom line, the average EPS estimate is $0.97.
Next year's average estimate for revenue is $22.81 billion. The average EPS estimate is $3.91.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 1,231 members out of 1,330 rating the stock outperform, and 99 members rating it underperform. Among 395 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 373 give Eli Lilly a green thumbs-up, and 22 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Eli Lilly is outperform, with an average price target of $56.29.
Can your portfolio provide you with enough income to last through retirement? You'll need more than Eli Lilly. Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks." Click here for instant access to this free report.
- Add Eli Lilly to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.